This study is in progress, not accepting new patients
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Summary
- Eligibility
- for people ages 18-70 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pharmacyclics LLC.
- ID
- NCT02910583
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 323 people participating
- Last Updated